World Health Organization (WHO) classification defines oral potentially malignant disorders (OPMD) as “clinical presentations that carry a risk of cancer development in the oral cavity, whether in clinically definable precursor lesions or in clinically normal oral mucosa”

OPMD estimated global prevalence is 4.47% in a recent meta-analysis. In Western countries, oral leukoplakia, oral lichen planus, and lichenoid lesions are the most prevalent (4.11%), males are more frequently affected, and tobacco is the most frequent cause. Squamous epithelial hyperplasia and dysplasia are the recognized histological substrates of OPMD. A meta-analysis showed an estimated mean for malignant transformation of 12%, ranging from 0% to 36%. Besides, OPMD shows a high rate of relapse. The proportion of oral cavity squamous cell carcinoma (OCSCC) preceded by OPMD is largely unknown. The early diagnosis and management of OPMD represent a unique opportunity to develop strategies that will prevent malignant transformation.

Keep up with the latest news,
subscribe our Newsletter


linkedin   x  

Project information

INTERCEPTOR aims to address the challenge of generating innovative and actionable pathways by engaging with the ‘critical practice’ dimensions of transformation.

A ‘critical practice’ approach explores transformation processes in practice across different dimensions which include research, policy, business, community and individual practices.

Action Contacts

Prof. Pierre Saintigny
Action Chair
+33(0)4 69 85 60 97

Prof. Senada Koljenovic
Action Vice Chair

COST Contacts

Dr Rosella Magli
Science Officer

Ms Carmencita Malimban
Administrative Officer


COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. www.cost.eu